Premium
Usefulness of troglitazone administration to obese hyperglycaemic patients with near‐normoglycaemia
Author(s) -
Sekino N.,
Kashiwabara A.,
Inoue T.,
Kawasaki T.,
Ogata N.,
Sawashige K.,
Yamanouchi T.
Publication year - 2003
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1046/j.1463-1326.2003.00248.x
Subject(s) - troglitazone , medicine , endocrinology , insulin , plasma glucose , oral administration , area under the curve , glucose tolerance test , insulin resistance , peroxisome , receptor
Aims: We assessed the effectiveness of 400 mg/day of troglitazone administered to hyperglycaemic patients with near‐normoglycaemia who were obese and who had hyperinsulinaemia. Results: The area under the plasma glucose curve in oral glucose tolerance tests (OGTT) significantly decreased from 39.8 ± 19.4–20.5 ± 10.2 mg/dL · h and the area under the insulin‐response curve from 31.8 ± 22.5–12.2 ± 5.7 μU/ml · h 4 months after the start of treatment. The level of HbA1c significantly improved from 6.6 ± 0.2 to 6.3 ± 0.2% (p < 0.05) by 1 month after administration, and that of serum 1,5‐anhydroglucitol (1,5‐AG) from 12.6 ± 1.1–18.3 ± 2.5 μ/ml (p < 0.05). In some cases, recovery of the first‐phase insulin secretion was observed. Conclusions: These findings suggest that the administration of this insulin sensitizer is useful in the treatment of obese Japanese subjects with borderline or mild diabetics accompanied by hyperinsulinaemia.